Author:
La Salvia Anna,Meyer May-Lucie,Hirsch Fred R.,Kerr Keith M.,Landi Lorenza,Tsao Ming-Sound,Cappuzzo Federico
Reference202 articles.
1. AbbVie. AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer. https://news.abbvie.com/news/press-releases/abbvie-announces-us-fda-granted-breakthrough-therapy-designation-btd-to-telisotuzumab-vedotin-teliso-v-for-previously-treated-non-small-cell-lung-cancer.htm (2022).
2. PD-L1 multiplex and quantitative image analysis for molecular diagnostics;Abdullahi Sidi;Cancers (Basel),2020
3. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01;Ahn;Annals of Oncology,2023
4. AstraZeneca. Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial. https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer.html (2023).
5. IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC, all questions answered?;Batra;J. Clin. Pathol.,2022